TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)


Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:





Indicator Windows:





YES
Refresh      
AMRN (Amarin Corporation plc)
Last Trade 17.71 Dividend/Share 0 PE Ratio -49.19
Date January 23-2019 Dividend Yield 0.000 Return on Assets -55.85
Change 0.19 ExDividend Date 0 Return on Capital null
Bid null Latest EPS -0.25 Price/Sale 37.638
Ask null LatestEPS Date 2017-12-31 Price to Book 49030.81
Volume null EPS ttm -0.360 Institutional % 52.4
Avg Volume 8.55M Shares Outstanding 326.29M Insider % 1
Open 17.91 Float 323.32M Short Ratio null
Prev Close 17.52 Return On Equity 145.01 5 Year Change % 9.357
High 18.16 Consensus EPS -0.08 2 Year Change % 5.107
Low 16.865 No. of Estimate 2.000 1 Year Change % 2.989
52 Week High 23.335 EPS Surprise $ null YTD Change % 0.361
52 Week Low 2.35 EPS Surprise Percent 0 6 Month Change % 5.258
52 Week Change 298.874 EBITDA 0M 3 Month Change % -0.174
50 Day MA 16.6958 Revenue 0M 1 Month Change % 0.427
200 Day MA Gross Profit 0M 5 Day Change % 0.066
Market Cap 5778.57M Cash 0M 30 Day Change % 0.062
Beta 1.156713 Debt 0M Stock Exchange NASDAQ Global Market
Sector Healthcare Revenue Per Share 0 Short Interest 0
Short Date 0 Revenue Per Employee 0 Short Ratio null
Data courtesy of IEX
Company Profile

Amarin Corporation plc operates as a biopharmaceutical company with a focus on cardiovascular diseases. Its cardiovascular programs focus in the field of lipid science and the known therapeutic benefits of essential fatty acids in cardiovascular disease. The company?s lead product candidate includes AMR101, a prescription grade Omega-3 product comprising ultra-pure ethyl eicosapentaenoic acid, which is entering Phase III clinical trials for the treatment of hypertriglyceridemia and mixed dyslipidemia. Its pipeline also includes programs in the area of central nervous system disorders, including Huntington?s disease, myasthenia gravis, and Parkinson?s disease. Amarin Corporation plc, formerly known as Ethical Holdings plc, was founded in 1989 and is based in Dublin, Ireland.